• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Neoantigen and local immune profile in ovarian clear cell carcinoma

Research Project

Project/Area Number 16K11152
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Obstetrics and gynecology
Research InstitutionSaitama Medical University

Principal Investigator

HASEGAWA Kosei  埼玉医科大学, 医学部, 教授 (30534193)

Co-Investigator(Kenkyū-buntansha) 松下 博和  愛知県がんセンター(研究所), 腫瘍免疫制御TR分野, 分野長 (80597782)
織田 克利  東京大学, 医学部附属病院, 准教授 (30359608)
Project Period (FY) 2016-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords卵巣明細胞癌 / 免疫 / ネオアンチゲン / T細胞 / 予後 / エクソーム / 癌 / 免疫学 / 卵巣
Outline of Final Research Achievements

A total of 74 cases of ovarian clear cell carcinoma (CCC) were analyzed in this study. Exome sequencing and expression array were performed. Mutations, neoantigen load, antigen presentation machinery and immune profile were investigated. The number of neoepitopes per mutation (neoantigen frequency, NF) was further analyzed. A correlation between high NF with decreased progression-free survival (PFS) was found. A cox multivariate regression analysis demonstrated that the high NF was an independent prognostic factor for PFS. Immune related genes were frequently highly expressed in tumors with low NF, suggesting evidence of immunoediting in the low NF group. In contrast, we observed decreased HLA class I expression as well as increased PD1/CD8 ratio in tumors with high NF. These results suggest that tumors with high NF in CCC might have received insufficient immunoediting due to an immunosuppressive tumor microenvironment.

Academic Significance and Societal Importance of the Research Achievements

卵巣明細胞癌74例のエクソームシーケンスデータを元に、腫瘍変異遺伝子情報からMHC class I 結合エピトープの予測を行ない、免疫編集に関して検討した。免疫編集とは腫瘍の発生、発育の段階で抗腫瘍免疫が働いた場合、ネオアンチゲンを持ったクローンが排除されるため、腫瘍の変異遺伝子数に比較してネオアンチゲンの数が減少する可能性が考えられている。そこで卵巣明細胞癌で免疫編集が起こっているかを確認するために、ネオアンチゲン数を変異遺伝子数で割ったものを免疫編集の指標(neoantigen frequency, NF)として検討した

Report

(4 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report
  • 2016 Research-status Report
  • Research Products

    (7 results)

All 2018 2017

All Journal Article (3 results) (of which Int'l Joint Research: 2 results,  Peer Reviewed: 3 results,  Open Access: 3 results) Presentation (4 results)

  • [Journal Article] Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.2018

    • Author(s)
      Oda K, Hamanishi J, Matsuo K, Hasegawa K
    • Journal Title

      Gynecol Oncol

      Volume: 151 Issue: 2 Pages: 381-389

    • DOI

      10.1016/j.ygyno.2018.09.001

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma2018

    • Author(s)
      Imai Yuichi、Hasegawa Kosei、Matsushita Hirokazu、Fujieda Nao、Sato Sho、Miyagi Etsuko、Kakimi Kazuhiro、Fujiwara Keiichi
    • Journal Title

      Oncology Letters

      Volume: 15 Pages: 6457-6468

    • DOI

      10.3892/ol.2018.8101

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma.2017

    • Author(s)
      Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K.
    • Journal Title

      Oncoimmunology

      Volume: 6 Issue: 8 Pages: e1338996-e1338996

    • DOI

      10.1080/2162402x.2017.1338996

    • Related Report
      2017 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] A subgroup with a T- cell inflamed phenotype in homologous recombination proficient high-grade serous ovarian carcinoma2018

    • Author(s)
      Kosei Hasegawa, Hirokazu Matsushita, Katsutoshi Oda, Shogo Yamamoto, Kayo Asada, Akira Yabuno Akira Nishijima, Takahiro Karasaki, Yuji Ikeda, Keiichi Fujiwara, Hiroyuki Aburatani and Kazuhiro Kakimi
    • Organizer
      The 77th Annual Meeting of the Japanese Cancer Association
    • Related Report
      2018 Annual Research Report
  • [Presentation] New Biomarker of Cancer Immunotherapy for Gynecologic Cancer2018

    • Author(s)
      Kosei Hasegawa
    • Organizer
      60th JSGO/ IGCS 2018
    • Related Report
      2018 Annual Research Report
  • [Presentation] Combination approaches of immunotherapy and targeted therapy in cancer treatment2018

    • Author(s)
      Kosei Hasegawa
    • Organizer
      60th JSGO/ IGCS 2018
    • Related Report
      2018 Annual Research Report
  • [Presentation] High frequency of neoantigens per mutation is a risk factor for recurrence in ovarian clear cell carcinoma2017

    • Author(s)
      Kosei Hasegawa
    • Organizer
      日本癌学会学術講演会
    • Related Report
      2017 Research-status Report

URL: 

Published: 2016-04-21   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi